Evaluation of a New Tranquillizer—WY 4036—in the Treatment of Anxiety

Abstract

Fifty patients (30 females and 20 males) suffering from a neurotic anxiety illness or from anxiety associated with depression were treated with WY 4036 or placebo in a double-blind controlled trial. The treatment lasted for three weeks. Patients were assessed before the start of the trial at intervals of one week, two weeks and three weeks. After the fourth and final assessment a four-point global assessment was also made and interpreted as `greatly improved', improved', 'no change', or `worse'.